BLCO Insider Trading

Insider Ownership Percentage: 0.15%
Insider Buying (Last 12 Months): $505,035.00
Insider Selling (Last 12 Months): $0.00

Bausch + Lomb Insider Trading History Chart

This chart shows the insider buying and selling history at Bausch + Lomb by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Bausch + Lomb Share Price & Price History

Current Price: $13.72
Price Change: Price Increase of +0.059 (0.43%)
As of 04/29/2025 03:14 PM ET

This chart shows the closing price history over time for BLCO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$13.65Closing price on 04/28/25:

Bausch + Lomb Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Bausch + Lomb (NYSE:BLCO)

11.07% of Bausch + Lomb stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BLCO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$189ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200M-$100M$0$100M$200MTotal InflowsTotal Outflows
Bausch + Lomb logo
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
Read More on Bausch + Lomb

Today's Range

Now: $13.72
Low: $13.57
High: $13.80

50 Day Range

MA: $14.21
Low: $10.93
High: $16.13

52 Week Range

Now: $13.72
Low: $10.46
High: $21.69

Volume

189,426 shs

Average Volume

624,271 shs

Market Capitalization

$4.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54

Who are the company insiders with the largest holdings of Bausch + Lomb?

Bausch + Lomb's top insider shareholders include:
  1. Brent L Saunders (CEO)
Learn More about top insider investors at Bausch + Lomb.

Who are the major institutional investors of Bausch + Lomb?

Bausch + Lomb's top institutional investors include:
  1. Renaissance Capital LLC — 0.02%
Learn More about top institutional investors of Bausch + Lomb stock.

Which major investors are selling Bausch + Lomb stock?

In the last quarter, BLCO stock was sold by these institutional investors:
  1. Renaissance Capital LLC